MSLE

Satellos Bioscience Inc.

Nasdaq · Pharmaceutical Preparations · Inc. Z4 · CIK 0001421642
$7.36 +5.22% $145.6M
High Impact Filing (8/10)
Vol
Market Cap$145.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Reddit Sentiment60° Warm
SEC Reports5
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. Z4·CIK 0001421642·Prev Close $6.99

Recent Activity

May 20, 2026 SEC
Satellos Bioscience Inc. filed its management information circular and proxy materials for the June 17, 2026 annual gene
6-K — Impact 2/10
May 15, 2026 SEC
Satellos Bioscience reported Q1 2026 financial results showing a net loss of $9.8M ($0.53 per share), widening from $6.1
6-K — Impact 5/10
May 15, 2026 SEC
Satellos reported Q1 2026 EPS of -$0.53, a GAAP miss vs consensus of -$0.59 (beat by 10.2%), but the Street-convention E
PRESS-RELEASE — Impact 5/10
May 15, 2026 earnings
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
<p align="justify">TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NAS

Price Targets

$27.67 +276.2% upside Strong Buy
Current $7.36 Low $20.00 Median $23.00 High $40.00 3 analysts
$20.00 $40.00

Analyst Ratings

Strong Buy89% buy · 9 analysts
3Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 18, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Apr 28, 2026 Guggenheim INITIATE Buy
Apr 6, 2026 Leerink Partners INITIATE Outperform
Mar 30, 2026 HC Wainwright & Co. MAINTAIN Buy → Buy
Mar 11, 2026 Cantor Fitzgerald INITIATE Overweight

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.42 ▲ +39.3% $-0.45 — $-0.40 2
Next Q $-0.40 ▲ +52.7% $-0.45 — $-0.34 2
Current FY $-1.73 ▲ +42.2% $-1.82 — $-1.64 -2% YoY 2
Next FY $-2.71 ▲ +18.6% $-4.48 — $-1.81 -57% YoY 3

Latest Reports

NEUTRAL 6-K 2/10
Satellos Bioscience Inc. filed its management information circular and proxy materials for the June 17, 2026 annual gene
May 20, 2026
NEUTRAL 6-K 5/10
Satellos Bioscience reported Q1 2026 financial results showing a net loss of $9.8M ($0.53 per share), widening from $6.1
May 15, 2026

Reddit Sentiment

60°
Warm
Bearish Neutral Bullish
1 mentions 1 bullish 0 bearish
∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

5 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 0 mixed, 4 neutral. Avg impact: 4.6/10.
NEUTRAL 6-K 2/10
Satellos Bioscience Inc. filed its management information circular and proxy materials for the June
May 20, 2026
NEUTRAL 6-K 5/10
Satellos Bioscience reported Q1 2026 financial results showing a net loss of $9.8M ($0.53 per share)
May 15, 2026
NEUTRAL PRESS-RELEASE 5/10
Satellos reported Q1 2026 EPS of -$0.53, a GAAP miss vs consensus of -$0.59 (beat by 10.2%), but the
May 15, 2026
NEUTRAL 6-K 3/10
Satellos Bioscience announced it will present at the Bloom Burton & Co. Healthcare Investor Conferen
Apr 9, 2026
BULLISH 6-K 8/10
Satellos Bioscience reported its 2025 financial results and highlighted significant clinical progres
Mar 27, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 3 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$27.67 mean target +276.2% upside Strong Buy (1.00)
$20.00 Low $40.00 High
MetricValue
Current Price$7.36
Target Low$20.00
Target Mean$27.67
Target Median$23.00
Target High$40.00
# Analysts3
RecommendationStrong Buy (1.00)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.42 $-0.45 $-0.40 — +39.3% 0↑ 1↓ $0.0B 0.0% 2
Next Q
2026-09-30
 $-0.40 $-0.45 $-0.34 — +52.7% 0↑ 1↓ $0.0B 0.0% 2
Current FY
2026-12-31
 $-1.73 $-1.82 $-1.64 -1.8% +42.2% 0↑ 1↓ $0.0B 0.0% 2
Next FY
2027-12-31
 $-2.71 $-4.48 $-1.81 -56.6% +18.6% — $0.0B 0.0% 3

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.425
7d ago$-0.700+0.275
30d ago$-0.700+0.275
60d ago$-0.480+0.055
90d ago$-5.760+5.335
4 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 18, 2026 HC Wainwright & Co. REITERATE Buy Buy
Apr 28, 2026 Guggenheim INITIATE — Buy
Apr 6, 2026 Leerink Partners INITIATE — Outperform
Mar 30, 2026 HC Wainwright & Co. MAINTAIN Buy Buy
Mar 11, 2026 Cantor Fitzgerald INITIATE — Overweight

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
May 1, 20263510089%
Apr 1, 20263510089%
Mar 1, 20263510089%
Feb 1, 20262510088%
Jan 1, 20262410086%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

60°
Warm
Bearish Neutral Bullish
1 mentions 1 bullish 0 bearish 1 time period

Reddit Sentiment History

DateMentionsSentimentBullishBearishThreads
Feb 16, 2026160° Warm101

Recent Reddit Threads

r/pennystocks Bullish 3mo ago
$MSLE | Steven Goldman Interviews Frank Gleeson, CEO of Satellos Bioscience
▲ 0 💬 1
May 15, 2026
earnings
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
<p align="justify">TORONTO, May 15, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“<strong>Satellos<
Apr 9, 2026
other
Satellos to Present at the Bloom Burton &amp; Co. Healthcare Investor Conference
<p align="justify">TORONTO, April 09, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“ <strong>Satell
Mar 27, 2026
earnings
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress
<p align="justify">TORONTO, March 27, 2026 (GLOBE NEWSWIRE) -- <strong>Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) </strong>(“ <strong>Satell